Find out how AAVantgarde Bio’s fully enrolled LUCE-1 Phase 1/2 trial advances AAVB-081 gene therapy development for Usher syndrome-related retinitis pigmentosa.
Swissmedic approves Santhera’s AGAMREE for Duchenne muscular dystrophy. Find out how vamorolone could reshape long-term steroid treatment strategies.
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.
Can UT Health San Antonio’s GRK2-targeted therapy reduce opioid use and scarring in burn trauma? Find out what’s next for this emerging dual-action approach.
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.
AskBio’s AB-1009 gene therapy for late-onset Pompe secures FDA IND clearance. Find out what this milestone means for AAV innovation and patient outlook.
TheraTears adds eyelid wipes and preservative-free drops for screen fatigue. Find out what this expansion means for OTC dry eye care and consumer trends.
Explore how Biocorneum’s dual-action bruise care system could reshape post-procedure recovery in aesthetic medicine. Read the strategic analysis now.
Find out how AIROS Medical’s five-year warranty on compression devices may shift durability standards and procurement expectations in lymphedema care.